Ghimire Roshan, Shrestha Rakshya, Amaradhi Radhika, Liu Lin, More Sunil, Ganesh Thota, Ford Alexandra K, Channappanavar Rudragouda
Department of Veterinary Pathobiology, College of Veterinary Medicine, Oklahoma State University, Stillwater, Oklahoma, USA.
Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA.
J Virol. 2025 May 20;99(5):e0166824. doi: 10.1128/jvi.01668-24. Epub 2025 Mar 31.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced impaired antiviral immunity and excessive inflammatory responses cause lethal pneumonia. However, the roles of key pattern recognition receptors that elicit protective antiviral and fatal inflammatory responses, specifically in the lungs, are not well described. Coronaviruses possess single-stranded RNA genome that activates TLR7/8 to induce an antiviral interferon (IFN) and robust inflammatory cytokine response. Here, using wild-type and TLR7-deficient (TLR7) mice infected with mouse-adapted SARS-CoV-2 (MA-CoV-2), we examined the role of TLR7 in the lung antiviral and inflammatory response and severe pneumonia. We showed that TLR7 deficiency significantly increased lung virus loads and morbidity/mortality, which correlated with reduced levels of type I IFNs (), type III IFNs (), and IFN-stimulated genes (ISGs) in the lungs. A detailed evaluation of MA-CoV-2-infected lungs revealed increased neutrophil accumulation and lung pathology in TLR7 mice. We further showed that blocking type I IFN receptor (IFNAR) signaling enhanced SARS-CoV-2 replication in the lungs and caused severe lung pathology, leading to 100% mortality compared to infected control mice. Moreover, immunohistochemical assessment of the lungs revealed increased numbers of SARS-CoV-2 antigen-positive macrophages, pneumocytes, and bronchial epithelial cells in TLR7 and IFNAR-deficient mice compared to control mice. In summary, we conclusively demonstrated that despite TLR7-induced robust lung inflammation, TLR7-induced IFN/ISG responses suppress lung virus replication and pathology and provide protection against SARS-CoV-2-induced fatal pneumonia. Additionally, given the similar disease outcomes in control, TLR7, and IFNAR-deficient MA-CoV-2-infected mice and coronavirus disease 2019 (COVID-19) patients, we propose that MA-CoV-2-infected mice constitute an excellent model for studying COVID-19.IMPORTANCESevere coronavirus disease 2019 (COVID-19) is caused by a delicate balance between a strong antiviral and an exuberant inflammatory response. A robust antiviral immunity and regulated inflammation are protective, while a weak antiviral response and excessive inflammation are detrimental. However, the key host immune sensors that elicit protective antiviral and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenge are poorly defined. Here, we examined the role of viral RNA-mediated TLR7 activation in the lung antiviral and inflammatory responses in SARS-CoV-2-infected mice. We demonstrate that TLR7 deficiency led to a high rate of morbidity and mortality, which correlated with an impaired antiviral interferon (IFN)-I/III response, enhanced lung virus replication, and severe lung pathology. Furthermore, we show that blocking IFN-I signaling using anti-IFN receptor antibody promoted SARS-CoV-2 replication in the lungs and caused severe disease. These results provide conclusive evidence that TLR7 and IFN-I receptor deficiencies lead to severe disease in mice, replicating clinical features observed in COVID-19 patients.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发的抗病毒免疫受损和过度炎症反应会导致致命性肺炎。然而,引发保护性抗病毒和致命性炎症反应的关键模式识别受体的作用,尤其是在肺部的作用,尚未得到充分描述。冠状病毒拥有单链RNA基因组,可激活TLR7/8以诱导抗病毒干扰素(IFN)和强烈的炎症细胞因子反应。在此,我们使用感染了小鼠适应性SARS-CoV-2(MA-CoV-2)的野生型和TLR7缺陷型(TLR7 -/-)小鼠,研究了TLR7在肺部抗病毒和炎症反应以及严重肺炎中的作用。我们发现,TLR7缺陷显著增加了肺部病毒载量以及发病率/死亡率,这与肺部I型干扰素(IFN-α)、III型干扰素(IFN-λ)和干扰素刺激基因(ISG)水平降低相关。对感染MA-CoV-2的肺部进行的详细评估显示,TLR7 -/-小鼠中中性粒细胞积累增加且肺部病理改变加重。我们进一步表明,阻断I型干扰素受体(IFNAR)信号增强了SARS-CoV-2在肺部的复制,并导致严重的肺部病理改变,与感染对照小鼠相比,死亡率达100%。此外,肺部免疫组化评估显示,与对照小鼠相比,TLR7 -/-和IFNAR缺陷小鼠中SARS-CoV-2抗原阳性的巨噬细胞、肺细胞和支气管上皮细胞数量增加。总之,我们确凿地证明,尽管TLR7会引发强烈的肺部炎症,但TLR7诱导的IFN/ISG反应可抑制肺部病毒复制和病理改变,并提供针对SARS-CoV-2诱导的致命性肺炎的保护作用。此外,鉴于对照、TLR7 -/-和IFNAR缺陷的感染MA-CoV-2小鼠与2019冠状病毒病(COVID-19)患者具有相似的疾病结局,我们提出感染MA-CoV-2的小鼠构成了研究COVID-19的优秀模型。
重要性
2019年严重冠状病毒病(COVID-19)是由强大的抗病毒反应与旺盛的炎症反应之间的微妙平衡所导致的。强大的抗病毒免疫力和受调控的炎症反应具有保护作用,而较弱的抗病毒反应和过度炎症则是有害的。然而,引发针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)挑战的保护性抗病毒和炎症反应的关键宿主免疫传感器尚不清楚。在此,我们研究了病毒RNA介导的TLR7激活在SARS-CoV-2感染小鼠肺部抗病毒和炎症反应中的作用。我们证明,TLR7缺陷导致高发病率和死亡率,这与抗病毒干扰素(IFN)-I/III反应受损、肺部病毒复制增强以及严重的肺部病理改变相关。此外,我们表明使用抗IFN受体抗体阻断IFN-I信号会促进SARS-CoV-2在肺部的复制并导致严重疾病。这些结果提供了确凿证据,表明TLR7和IFN-I受体缺陷会导致小鼠出现严重疾病,重现了COVID-19患者中观察到的临床特征。